Kevin Kelly, MD
Hematology & Oncology · Los Angeles, CANPI 1093963712
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $765,958 of the $894,156 with a category attached, or 85.7%. 28 manufacturers reported payments, led by Johnson & Johnson at 27.8% of the total. Reporting peaked in 2022 at $189,281 and has fallen 59.1% since, to $77,369 in 2025. Among hematology & oncology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 790 payments — averaging $1131.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$248K
- AstraZeneca$155K
- Karyopharm Therapeutics Inc.$145K
- Seagen Inc.$55K
- Bristol Myers Squibb$52K
- Lilly USA, LLC$42K
- plus $197K from 22 others
Across 112 payments — averaging $22,430 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$1.1M
- Trillium Therapeutics USA, LLC$627K
- Merck$562K
- Beone Medicines Ltd.$92K
- Pfizer$39K
- Beone Medicines USA, Inc.$36K
- plus $89K from 5 others
What the payments were for
- Consulting fees$47,8275%
- Speaking & faculty fees$765,95886%
- Travel & lodging$56,2406%
- Food & beverage$23,9143%
- Education$2170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 242 | $248,376 |
| AstraZeneca | 146 | $154,508 |
| Karyopharm Therapeutics Inc. | 111 | $144,936 |
| Seagen Inc. | 60 | $55,122 |
| Bristol Myers Squibb | 32 | $52,370 |
| Lilly USA, LLC | 27 | $42,245 |
| Epizyme, Inc. | 23 | $29,539 |
| GSK | 16 | $27,769 |
| Pharmacyclics LLC, An Abbvie Company | 23 | $24,119 |
| E.r. Squibb & Sons, L.L.C. | 10 | $22,041 |
| Ipsen Biopharmaceuticals, Inc | 10 | $19,860 |
| Incyte Corporation | 12 | $14,295 |
| ADC Therapeutics America, Inc. | 15 | $13,816 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $10,574 |
| Servier Pharmaceuticals LLC | 10 | $7,971 |
| Bayer | 4 | $5,343 |
| Genentech USA, Inc. | 8 | $4,763 |
| Sanofi | 4 | $3,946 |
| AbbVie | 8 | $3,373 |
| Gilead(2 entities) | 6 | $3,240 |
| Novartis | 2 | $3,222 |
| Janssen Scientific Affairs, LLC | 1 | $1,635 |
| TG Therapeutics, Inc. | 1 | $450 |
| F. Hoffmann-la Roche AG | 2 | $393 |
| Astellas Pharma US Inc | 3 | $181 |
| Pfizer | 3 | $33 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$894,156 in reported general payments places this provider in the 95th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 32 | $535,245 |
| Lenalidomide | 22 | $309,181 |
| PomalystPomalidomide | 14 | $303,876 |
| Acyclovir | 34 | $594 |
| Ondansetron Hcl | 13 | $75 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 17 | $35 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $52,370 | $535,24532 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $22,041 | $303,87614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in Los Angeles
- Dennis SlamonLos Angeles$3.1M
- George YaghmourLos Angeles$1.9M
- Raghuveer RanganathanLos Angeles$609K
- Matthew RettigLos Angeles$442K
- David BerzLos Angeles$420K
- Gottfried KonecnyLos Angeles$402K
- Antoni RibasLos Angeles$315K
- Edward GaronLos Angeles$301K
- Rahul NaikLos Angeles$297K
- Sandra HorningStanford$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.